Participant flow33

How many started, completed or left each group, period by period.

21 to 33 of 33

Period	Milestone	Group	Participants
Randomized Double-blind Period	STARTED	Placebo	687
Randomized Double-blind Period	On-treatment Completers	All Subjects Prerandomization	0
Randomized Double-blind Period	On-treatment Completers	Tolvaptan	578
Randomized Double-blind Period	On-treatment Completers	Placebo	637
Randomized Double-blind Period	Off-treatment Completers	All Subjects Prerandomization	0
Randomized Double-blind Period	Off-treatment Completers	Tolvaptan	76
Randomized Double-blind Period	Off-treatment Completers	Placebo	22
Randomized Double-blind Period	COMPLETED	All Subjects Prerandomization	0
Randomized Double-blind Period	COMPLETED	Tolvaptan	654
Randomized Double-blind Period	COMPLETED	Placebo	659
Randomized Double-blind Period	NOT COMPLETED	All Subjects Prerandomization	0
Randomized Double-blind Period	NOT COMPLETED	Tolvaptan	29
Randomized Double-blind Period	NOT COMPLETED	Placebo	28

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02160145/flow?page=2